il-2 derived from both natural ( jurkat human t-cell tumor ) and recombinant ( escherichia coli ) sources has been studied in phase i protocols designed to evaluate toxicity in patients with a variety of solid tumors and to ascertain improvement in clinical parameters and immunologic status .
C0021756
il-2
C0086418
human